$337M | ||
$259M | ||
$60M | ||
$58M | ||
$50M | ||
$50M |
Buys | $79,042,965 | 4 | 14 |
Sells | $133,734,619 | 25 | 86 |
RA CAPITAL MANAGEMENT, L.P. | 4 | $79.04M | 0 | $0 | $79.04M | |
Lichter Jay | 10 percent owner | 0 | $0 | 1 | $178,084 | $-178,084 |
DiRaimondo Thomas | Chief Scientific Officer | 0 | $0 | 1 | $231,716 | $-231,716 |
Meyer Andrew Hollman | Chief Business Officer | 0 | $0 | 7 | $3.58M | $-3.58M |
Campbell David Alan | President and CEO | 0 | $0 | 6 | $6.5M | $-6.5M |
Avalon Ventures XI, L.P. | 10 percent owner | 0 | $0 | 10 | $123.25M | $-123.25M |
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Over the last 12 months, insiders at Janux Therapeutics, Inc. have bought $79.04M and sold $133.73M worth of Janux Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Janux Therapeutics, Inc. have bought $69.09M and sold $121.4M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $79.04M.
The last purchase of 110,206 shares for transaction amount of $3.42M was made by RA CAPITAL MANAGEMENT, L.P. () on 2025‑03‑07.
2025-05-01 | Sale | Meyer Andrew Hollman | Chief Business Officer | 2,933 0.0049% | $31.95 | $93,703 | -21.18% | |
2025-05-01 | Sale | Meyer Andrew Hollman | Chief Business Officer | 3,333 0.0056% | $32.03 | $106,745 | -21.18% | |
2025-04-21 | Sale | Meyer Andrew Hollman | Chief Business Officer | 3,334 0.0069% | $30.00 | $100,020 | -12.74% | |
2025-03-07 | RA CAPITAL MANAGEMENT, L.P. | 110,206 0.187% | $31.02 | $3.42M | -11.90% | |||
2025-03-06 | RA CAPITAL MANAGEMENT, L.P. | 372,093 0.6366% | $30.78 | $11.45M | -12.20% | |||
2025-03-05 | RA CAPITAL MANAGEMENT, L.P. | 341,742 0.5742% | $30.64 | $10.47M | -12.51% | |||
2025-03-03 | Sale | Meyer Andrew Hollman | Chief Business Officer | 3,334 0.0059% | $32.15 | $107,174 | -11.45% | |
2025-02-03 | Sale | Meyer Andrew Hollman | Chief Business Officer | 3,334 0.0056% | $42.29 | $140,999 | -29.21% | |
2025-01-07 | Sale | Campbell David Alan | President and CEO | 5,000 0.009% | $60.00 | $300,004 | -46.96% | |
2025-01-02 | Sale | Meyer Andrew Hollman | Chief Business Officer | 13,334 0.0234% | $54.88 | $731,785 | -42.24% | |
2024-12-24 | Sale | Campbell David Alan | President and CEO | 25,000 0.0433% | $56.19 | $1.4M | -44.92% | |
2024-12-03 | Sale | Campbell David Alan | President and CEO | 15,000 0.0317% | $67.00 | $1M | -46.86% | |
2024-11-25 | Sale | Campbell David Alan | President and CEO | 25,000 0.0505% | $51.60 | $1.29M | -34.39% | |
2024-10-28 | Sale | Campbell David Alan | President and CEO | 25,000 0.0486% | $53.54 | $1.34M | -35.99% | |
2024-10-18 | Sale | Avalon Ventures XI, L.P. | 10 percent owner | 1.46M 2.5633% | $45.76 | $66.9M | -26.89% | |
2024-10-18 | RA CAPITAL MANAGEMENT, L.P. | 1.2M 2.0576% | $44.75 | $53.7M | -26.89% | |||
2024-10-17 | Sale | Avalon Ventures XI, L.P. | 10 percent owner | 1,843 0.0035% | $50.02 | $92,187 | -26.16% | |
2024-10-16 | Sale | Avalon Ventures XI, L.P. | 10 percent owner | 209,516 0.4311% | $50.03 | $10.48M | -25.25% | |
2024-09-30 | Sale | Avalon Ventures XI, L.P. | 10 percent owner | 958 0.0018% | $46.24 | $44,298 | -12.45% | |
2024-09-27 | Sale | Campbell David Alan | President and CEO | 25,000 0.0476% | $46.31 | $1.16M | -13.12% |
RA CAPITAL MANAGEMENT, L.P. | 10141287 17.1377% | $252.52M | 6 | 0 | +1.61% | |
Avalon Ventures XI, L.P. | 10 percent owner | 401321 0.6782% | $9.99M | 2 | 11 | +1.61% |
Campbell David Alan | President and CEO | 293054 0.4952% | $7.3M | 0 | 6 | |
DiRaimondo Thomas | Chief Scientific Officer | 97938 0.1655% | $2.44M | 0 | 1 | |
Meyer Andrew Hollman | Chief Business Officer | 82139 0.1388% | $2.05M | 0 | 7 | |
Lichter Jay | 10 percent owner | 7000 0.0118% | $174,300.00 | 2 | 2 | +1.61% |
Bregua Corp | 10 percent owner | 3749250 6.3358% | $93.36M | 1 | 0 | +1.61% |
Reardon Tighe | Acting Chief Financial Officer | 633673 1.0708% | $15.78M | 2 | 1 | +1.61% |
ORBIMED ADVISORS LLC | director | 231098 0.3905% | $5.75M | 1 | 3 | +1.61% |
Thompson Peter A. | director | 231098 0.3905% | $5.75M | 1 | 3 | +1.61% |
$8,217,280 | 112 | 46.33% | $1.12B | |
$831,902,292 | 108 | 9.34% | $1.13B | |
$54,590,806 | 65 | 21.84% | $1.39B | |
$11,583,737 | 45 | 49.75% | $1.29B | |
$100,002,191 | 42 | 21.48% | $1.21B | |
$530,111,731 | 35 | 8.69% | $1.36B | |
$148,770,544 | 34 | 80.63% | $1.45B | |
$309,951,506 | 30 | 32.56% | $1.52B | |
$1,295,059 | 29 | 102.78% | $1.41B | |
$150,253,463 | 26 | -52.83% | $1.65B | |
$96,400,802 | 19 | 32.48% | $1.58B | |
$92,580,864 | 14 | -1.28% | $1.61B | |
$137,027,226 | 13 | 28.32% | $1.6B | |
$43,198,628 | 12 | -0.10% | $1.3B | |
$32,575,266 | 8 | 37.03% | $1.72B | |
Janux Therapeutics, Inc. (JANX) | $107,098,946 | 7 | 1.61% | $1.47B |
$21,792,890 | 6 | 75.72% | $1.51B | |
$91,325,021 | 6 | 1.83% | $1.64B | |
$5,000,000 | 1 | -22.84% | $1.57B |
Increased Positions | 115 | +52.75% | 10M | +14.99% |
Decreased Positions | 98 | -44.95% | 7M | -10.94% |
New Positions | 21 | New | 682,315 | New |
Sold Out Positions | 53 | Sold Out | 3M | Sold Out |
Total Postitions | 235 | +7.8% | 67M | +4.05% |
Ra Capital Management, L.P. | $340,823.00 | 17.57% | 10.37M | +1M | +13.09% | 2024-12-31 |
Fmr Llc | $285,068.00 | 14.7% | 8.67M | +845,266 | +10.8% | 2024-12-31 |
Janus Henderson Group Plc | $117,132.00 | 6.04% | 3.56M | +1M | +41.17% | 2024-12-31 |
Paradigm Biocapital Advisors Lp | $115,606.00 | 5.96% | 3.52M | +1M | +46.46% | 2024-12-31 |
Adage Capital Partners Gp, L.L.C. | $100,670.00 | 5.19% | 3.06M | +986,750 | +47.55% | 2024-12-31 |
Blackrock, Inc. | $94,463.00 | 4.87% | 2.87M | +147,146 | +5.4% | 2025-03-31 |
Vanguard Group Inc | $70,243.00 | 3.62% | 2.14M | +288,402 | +15.61% | 2024-12-31 |
Cormorant Asset Management, Lp | $69,048.00 | 3.56% | 2.1M | +1M | New | 2024-12-31 |
Woodline Partners Lp | $60,900.00 | 3.14% | 1.85M | +251,924 | +15.74% | 2024-12-31 |
Ecor1 Capital, Llc | $48,328.00 | 2.49% | 1.47M | 0 | 0% | 2024-12-31 |